Extra-Cellular Vesicles Derived from Thyroid Cancer Cells Promote the Epithelial to Mesenchymal Transition (EMT) and the Transfer of Malignant Phenotypes through Immune Mediated Mechanisms.
EMT
HMGB1
extra-cellular vesicles
microRNAs
thyroid cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
01 Feb 2023
01 Feb 2023
Historique:
received:
19
12
2022
revised:
27
01
2023
accepted:
28
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
15
2
2023
Statut:
epublish
Résumé
Thyroid cancer is the most common endocrine cancer, and its incidence is increasing in many countries around the world. Among thyroid cancers, the papillary thyroid cancer (PTC) histotype is particularly prevalent. A small percentage of papillary tumors is associated with metastases and aggressive behavior due to de-differentiation obtained through the epithelial-mesenchymal transition (EMT) by which epithelial thyroid cells acquire a fibroblast-like morphology, reduce cellular adhesion, increase motility and expression of mesenchymal proteins. The tumor microenvironment plays an important role in promoting an aggressive phenotype through hypoxia and the secretion of HMGB1 and other factors. Hypoxia has been shown to drastically change the tumor cell phenotype and has been associated with increasing metastatic and migratory behavior. Cells transfer information to neighboring cells or distant locations by releasing extracellular membrane vesicles (EVs) that contain key molecules, such as mRNAs, microRNAs (miRNAs), and proteins, that are able to modify protein expression in recipient cells. In this study, we investigated the potential role of EVs released by the anaplastic cancer cell line CAL-62 in inducing a malignant phenotype in a papillary cancer cell line (BCPAP).
Identifiants
pubmed: 36769076
pii: ijms24032754
doi: 10.3390/ijms24032754
pmc: PMC9917007
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Res. 2019 Sep 15;79(18):4557-4566
pubmed: 31350295
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
J Clin Invest. 2013 Oct;123(10):4390-404
pubmed: 23999427
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Biomed Res Int. 2015;2015:512027
pubmed: 26106610
Biochim Biophys Acta Rev Cancer. 2018 Jan;1869(1):64-77
pubmed: 29175553
Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42
pubmed: 16493418
Front Endocrinol (Lausanne). 2021 Apr 27;11:637826
pubmed: 33986723
Oncoimmunology. 2016 Mar 30;5(6):e1168556
pubmed: 27471646
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Cell Mol Life Sci. 2013 Dec;70(23):4463-77
pubmed: 23715860
Nat Cell Biol. 2000 Feb;2(2):76-83
pubmed: 10655586
Int J Mol Sci. 2019 Dec 18;21(1):
pubmed: 31861373
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Mol Cancer. 2019 Mar 30;18(1):55
pubmed: 30925923
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Biomed Pharmacother. 2020 Feb;122:109687
pubmed: 31918267
Pharmacol Ther. 2018 Aug;188:1-11
pubmed: 29476772
Cancer Lett. 2020 Sep 1;487:10-20
pubmed: 32470488
J Thyroid Res. 2012;2012:618985
pubmed: 22530159
Cells. 2021 Jul 06;10(7):
pubmed: 34359884
J Cancer Epidemiol. 2013;2013:965212
pubmed: 23737785
Endocr Relat Cancer. 2019 May;26(5):525-538
pubmed: 30870812
Oncol Res. 2017 Sep 21;25(8):1215-1222
pubmed: 27938505
Nat Rev Immunol. 2005 Apr;5(4):331-42
pubmed: 15803152
Cancer Res. 2007 Sep 1;67(17):8113-20
pubmed: 17804723
Med Sci Monit. 2019 Apr 01;25:2352-2360
pubmed: 30930461
Cell Oncol (Dordr). 2020 Apr;43(2):177-193
pubmed: 31677065
Nat Rev Mol Cell Biol. 2018 Apr;19(4):213-228
pubmed: 29339798
Nat Rev Mol Cell Biol. 2014 Mar;15(3):178-96
pubmed: 24556840
Adv Protein Chem Struct Biol. 2017;107:37-76
pubmed: 28215228
Virchows Arch. 2012 Jun;460(6):587-600
pubmed: 22527019
J Exp Med. 2012 Aug 27;209(9):1519-28
pubmed: 22869893
Eur J Med Chem. 2012 Mar;49:24-40
pubmed: 22305612
Nat Rev Cancer. 2013 Feb;13(2):97-110
pubmed: 23344542
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Nat Cell Biol. 2019 Jan;21(1):9-17
pubmed: 30602770
Clin Cancer Res. 2013 Aug 1;19(15):4046-57
pubmed: 23723299
Curr Mol Med. 2018;18(6):343-351
pubmed: 30411685
Oncol Lett. 2019 Jun;17(6):5292-5300
pubmed: 31186746
Oncotarget. 2015 Mar 30;6(9):6472-98
pubmed: 25762624
Oncogene. 2015 Nov 26;34(48):5857-68
pubmed: 25867073
Eur J Immunol. 2015 Apr;45(4):1216-27
pubmed: 25545169
Oncotarget. 2018 Apr 17;9(29):20838-20854
pubmed: 29755694
Oncol Rep. 2012 Dec;28(6):2285-9
pubmed: 23023232
Cells. 2021 Mar 03;10(3):
pubmed: 33802627
Oncol Lett. 2018 Nov;16(5):6815-6821
pubmed: 30333891